Loading...
TerrAscend Corp.
TRSSF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.72
$-0.23(-11.79%)

Financial performance has remained strong, with revenue growing from $117.90M in Q4 2023 to $74.17M in Q3 2024. Gross profit continued to perform well, with margins at 49% in the latest quarter. Operating income reached $2.45M in Q3 2024, holding a steady 3% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $7.30M. Net income dropped to -$23.15M, keeping EPS at -$0.08. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan